Amedisys Yönetim

Yönetim kriter kontrolleri 1/4

Amedisys CEO'su Richard Ashworth, Apr2023 tarihinde atandı, in görev süresi 1.58 yıldır. in toplam yıllık tazminatı $ 16.97M olup, şirket hissesi ve opsiyonları dahil olmak üzere 4.1% maaş ve 95.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.088% ine doğrudan sahiptir ve bu hisseler MX$ 55.76M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.6 yıl ve 5 yıldır.

Anahtar bilgiler

Richard Ashworth

İcra Kurulu Başkanı

US$17.0m

Toplam tazminat

CEO maaş yüzdesi	4.1%
CEO görev süresi	1.6yrs
CEO sahipliği	0.09%
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Richard Ashworth'un ücretlendirmesi Amedisys'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$92m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$17m	US$692k	-US$10m

Tazminat ve Piyasa: Richard 'nin toplam tazminatı ($USD 16.97M ), MX pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.22M ).

Tazminat ve Kazançlar: Richard şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Richard Ashworth (49 yo)

1.6yrs

Görev süresi

US$16,974,025

Tazminat

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Ashworth	President	1.6yrs	US$16.97m	0.088% MX$ 55.8m
Scott Ginn	Executive VP	7.1yrs	US$4.45m	0.077% MX$ 48.7m
Denise Bohnert	Chief Compliance Officer	5.2yrs	US$1.28m	Veri yok
Nick Muscato	Chief Strategy Officer	no data	US$1.37m	0.0065% MX$ 4.1m
Allyson Guidroz	Chief Accounting Officer & Principal Accounting Officer	1.3yrs	Veri yok	0.0097% MX$ 6.1m
Pete Hartley	CTO & Senior VP of Business Operations Systems	no data	Veri yok	Veri yok
Keith Blanchard	Acting Chief Information Officer	less than a year	Veri yok	Veri yok
Jennifer Griffin	Senior VP	2.1yrs	Veri yok	Veri yok
Kendra Kimmons	VP of Marketing & Communications & Media Relations	no data	Veri yok	Veri yok
Caitlin Franklin	Acting Chief People Officer	less than a year	Veri yok	Veri yok
Francis Mayer	Senior Vice President of Development	no data	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

47.5yo

Ortalama Yaş

Deneyimli Yönetim: AMED * 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Ashworth	President	1.6yrs	US$16.97m	0.088% MX$ 55.8m
Paul Kusserow	Chairman	9.9yrs	US$4.00m	1.33% MX$ 844.9m
Bruce Perkins	Independent Director	9.6yrs	US$267.62k	0.063% MX$ 40.1m
Vickie Capps	Independent Director	5yrs	US$277.62k	0.020% MX$ 12.5m
Molly Coye	Independent Director	5yrs	US$267.62k	0.017% MX$ 10.6m
Julie Klapstein	Lead Independent DIrector	8.6yrs	US$282.62k	0.039% MX$ 24.5m
Jeffrey Rideout	Independent Director	8.6yrs	US$267.62k	0.018% MX$ 11.6m
Teresa Kline	Independent Director	5yrs	US$272.62k	0.020% MX$ 12.5m
Ivanetta Samuels	Independent Director	3.9yrs	US$252.62k	0.013% MX$ 8.2m

5.0yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AMED * 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).

Amedisys Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Recent updates

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

High number of new directors

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

High number of new directors

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

High number of new directors

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

High number of new directors

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$3.0m worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Investor sentiment improved over the past week

High number of new directors

High number of new directors

Independent Director recently sold Mex$42m worth of stock

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

Investor sentiment deteriorated over the past week

High number of new directors

President & COO recently sold Mex$1.5m worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold Mex$10m worth of stock

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

Independent Director recently bought Mex$5.3m worth of stock

Revenue misses expectations

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Defensive Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi